Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki

Detalles Bibliográficos
Autores principales: Hashimoto, Yaeko, Suzuki, Takuji, Hashimoto, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985059/
https://www.ncbi.nlm.nih.gov/pubmed/35388183
http://dx.doi.org/10.1038/s41380-022-01546-2
_version_ 1784682292418969600
author Hashimoto, Yaeko
Suzuki, Takuji
Hashimoto, Kenji
author_facet Hashimoto, Yaeko
Suzuki, Takuji
Hashimoto, Kenji
author_sort Hashimoto, Yaeko
collection PubMed
description
format Online
Article
Text
id pubmed-8985059
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89850592022-04-06 Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki Hashimoto, Yaeko Suzuki, Takuji Hashimoto, Kenji Mol Psychiatry Correspondence Nature Publishing Group UK 2022-04-06 2022 /pmc/articles/PMC8985059/ /pubmed/35388183 http://dx.doi.org/10.1038/s41380-022-01546-2 Text en © The Author(s), under exclusive licence to Springer Nature Limited 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Correspondence
Hashimoto, Yaeko
Suzuki, Takuji
Hashimoto, Kenji
Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
title Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
title_full Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
title_fullStr Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
title_full_unstemmed Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
title_short Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
title_sort comments to “fluvoxamine and long covid-19: a new role for sigma-1 receptor (s1r) agonists” by khani and entezari-maleki
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985059/
https://www.ncbi.nlm.nih.gov/pubmed/35388183
http://dx.doi.org/10.1038/s41380-022-01546-2
work_keys_str_mv AT hashimotoyaeko commentstofluvoxamineandlongcovid19anewroleforsigma1receptors1ragonistsbykhaniandentezarimaleki
AT suzukitakuji commentstofluvoxamineandlongcovid19anewroleforsigma1receptors1ragonistsbykhaniandentezarimaleki
AT hashimotokenji commentstofluvoxamineandlongcovid19anewroleforsigma1receptors1ragonistsbykhaniandentezarimaleki

Ejemplares similares